文献速递心脑血管急症消化、代谢与肾脏急症

别嘌醇与常规治疗在英國缺血性心脏病患者中的比较(ALL-HEART):一项多中心、前瞻性、随机、开放标签、盲法终点试验

Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial.
PubMed 文献 · Lancet · 2022-01-01
一句话结论在60岁及以上无痛风史的缺血性心脏病患者中,别嘌醇600 mg/日(中度肾损者300 mg/日)与常规治疗相比,主要心血管复合终点无差异(HR 1.04,95%CI 0.89-1.21,p=0.65)。

ALL-HEART是一项在英格兰和苏格兰18个区域中心、424个初级保健诊所招募的多中心、前瞻性、随机、开放标签、盲法终点试验。纳入60岁及以上、有缺血性心脏病但无痛风史的患者,随机接受口服别嘌醇(上调至600 mg/日,基线中度肾损者300 mg/日)或继续常规治疗。主要终点为非致死性心肌梗死、非致死性卒中或心血管死亡的复合终点。改良意向性治疗人群5721例(别嘌醇组2853例,常规治疗组2868例),平均随访4.8年(SD 1.5),主要终点事件别嘌醇组314例(11.0%,2.47/100患者年)vs 常规治疗组325例(11.3%,2.37/100患者年),HR 1.04(95%CI 0.89-1.21),p=0.65;全因死亡288例(10.1%)vs 303例(10.6%),HR 1.02(95%CI 0.87-1.20),p=0.77。结论:在该人群中,别嘌醇治疗与常规治疗的主要心血管结局无差异。

要点

  • 60岁及以上、缺血性心脏病、无痛风史患者中,别嘌醇组主要终点314/2853(11.0%,2.47/100患者年)vs 常规治疗组325/2868(11.3%,2.37/100患者年),HR 1.04(95%CI 0.89-1.21),p=0.65。
  • 全因死亡别嘌醇组288/2853(10.1%)vs 常规治疗组303/2868(10.6%),HR 1.02(95%CI 0.87-1.20),p=0.77。
  • 别嘌醇用法:口服,上调至600 mg/日;基线中度肾损伤者300 mg/日。
  • 该试验未显示别嘌醇改善缺血性心脏病患者的主要心血管结局。

适用人群与场景

  • 年龄60岁及以上、有缺血性心脏病但无痛风史的患者,从英格兰和苏格兰424个初级保健诊所招募。

处置流程与药物剂量

  • 别嘌醇组:口服别嘌醇,上调至600 mg/日;基线中度肾损伤者300 mg/日。
  • 对照组:继续常规治疗。

研究设计与关键结果

  • 多中心、前瞻性、随机、开放标签、盲法终点试验,18个区域中心,424个初级保健诊所招募;2014年2月7日至2017年10月2日入组5937例,随机后排除216例,改良意向性治疗人群5721例(平均年龄72.0岁[SD 6.8],男性4321例[75.5%],白人5676例[99.2%]),别嘌醇组2853例,常规治疗组2868例。
  • 主要终点(非致死性心肌梗死、非致死性卒中或心血管死亡复合终点):别嘌醇组314例(11.0%,2.47/100患者年)vs 常规治疗组325例(11.3%,2.37/100患者年),HR 1.04(95%CI 0.89-1.21),p=0.65。
  • 全因死亡:别嘌醇组288例(10.1%)vs 常规治疗组303例(10.6%),HR 1.02(95%CI 0.87-1.20),p=0.77。
  • 平均随访时间4.8年(SD 1.5)。

证据类型、等级与局限

  • 证据类型:多中心、前瞻性、随机、开放标签、盲法终点试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在60岁及以上、有缺血性心脏病但无痛风史的患者中,别嘌醇治疗与常规治疗的主要心血管结局无差异。
  • 原文未据此给出推荐。

指南或共识出处

  • ALL-HEART试验,注册号EU Clinical Trials Register EudraCT 2013-003559-39,ISRCTN32017426;资助:UK National Institute for Health and Care Research。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Allopurinol is a urate-lowering therapy used to treat patients with gout. Previous studies have shown that allopurinol has positive effects on several cardiovascular parameters. The ALL-HEART study aimed to determine whether allopurinol therapy improves major cardiovascular outcomes in patients with ischaemic heart disease.

METHODS: ALL-HEART was a multicentre, prospective, randomised, open-label, blinded-endpoint trial done in 18 regional centres in England and Scotland, with patients recruited from 424 primary care practices. Eligible patients were aged 60 years or older, with ischaemic heart disease but no history of gout. Participants were randomly assigned (1:1), using a central web-based randomisation system accessed via a web-based application or an interactive voice response system, to receive oral allopurinol up-titrated to a dose of 600 mg daily (300 mg daily in participants with moderate renal impairment at baseline) or to continue usual care. The primary outcome was the composite cardiovascular endpoint of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death. The hazard ratio (allopurinol vs usual care) in a Cox proportional hazards model was assessed for superiority in a modified intention-to-treat analysis (excluding randomly assigned patients later found to have met one of the exclusion criteria). The safety analysis population included all patients in the modified intention-to-treat usual care group and those who took at least one dose of randomised medication in the allopurinol group. This study is registered with the EU Clinical Trials Register, EudraCT 2013-003559-39, and ISRCTN, ISRCTN32017426.

FINDINGS: Between Feb 7, 2014, and Oct 2, 2017, 5937 participants were enrolled and then randomly assigned to receive allopurinol or usual care. After exclusion of 216 patients after randomisation, 5721 participants (mean age 72·0 years [SD 6·8], 4321 [75·5%] males, and 5676 [99·2%] white) were included in the modified intention-to-treat population, with 2853 in the allopurinol group and 2868 in the usual care group. Mean follow-up time in the study was 4·8 years (1·5). There was no evidence of a difference between the randomised treatment groups in the rates of the primary endpoint. 314 (11·0%) participants in the allopurinol group (2·47 events per 100 patient-years) and 325 (11·3%) in the usual care group (2·37 events per 100 patient-years) had a primary endpoint (hazard ratio [HR] 1·04 [95% CI 0·89-1·21], p=0·65). 288 (10·1%) participants in the allopurinol group and 303 (10·6%) participants in the usual care group died from any cause (HR 1·02 [95% CI 0·87-1·20], p=0·77).

INTERPRETATION: In this large, randomised clinical trial in patients aged 60 years or older with ischaemic heart disease but no history of gout, there was no difference in the primary outcome of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death between participants randomised to allopurinol therapy and those randomised to usual care.

FUNDING: UK National Institute for Health and Care Research.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Mackenzie IS, Hawkey CJ, Ford I, et al. Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial. Lancet. 2022. PMID: 36216006. doi:10.1016/S0140-6736(22)01657-9

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。